Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2025-03-30 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于变更经营范围、修订《公司章程》并办理工商变更登记的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the company's board regarding changes to the company's business scope and amendments to the Articles of Association, which require shareholder approval and subsequent registration with the industrial and commercial authorities. It is a formal notice about corporate governance and operational scope changes, not a financial report, earnings release, or regulatory certification. The document does not contain financial data or results but focuses on governance and company structure changes. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in company management or governance-related matters.
2025-03-30 Chinese
迈威生物2024年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2024年度董事会审计委员会履职情况报告" which translates to "2024 Annual Board Audit Committee Performance Report." It details the activities, meetings, and oversight functions of the audit committee throughout the year 2024, including reviews of financial reports, internal controls, and external audit work. The document is a detailed report on the audit committee's duties and performance rather than a standalone audit report or an annual report. It does not contain full financial statements or comprehensive company financial performance data but focuses on the audit committee's supervisory role and activities. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related committee reports on audit and internal controls, excluding full annual reports. The document length is 3687 characters, which is sufficient for a detailed committee report but not a full annual report. Therefore, the classification is AR with high confidence.
2025-03-30 Chinese
迈威生物关于部分募集资金投资项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the completion (结项) of a fundraising investment project and the permanent allocation of surplus raised funds to working capital. It details the use of proceeds from an IPO, the status of the raised funds, and approvals from the board, supervisory committee, and independent directors. It also includes regulatory references and states that the matter will be submitted to the shareholders' meeting for approval. The document is a formal disclosure about the use and management of capital raised through equity issuance, specifically about the investment project completion and fund allocation. This fits the definition of a Capital/Financing Update (CAP), as it provides updates on fundraising and capital usage activities. The document is not a full financial report, audit, or earnings release, nor is it a voting result or management change announcement. It is a detailed capital usage update with regulatory compliance information.
2025-03-30 Chinese
迈威生物2024年度内部控制审计报告
Regulatory Filings
2025-03-30 Chinese
迈威生物关于召开2024年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of the company, including the date, voting methods, meeting agenda, and instructions for shareholders. It lists the proposals to be voted on, such as approval of the 2024 annual report, financial budget, profit distribution, audit firm reappointment, and other governance matters. The document also includes procedural details for attendance and proxy voting. There is no actual financial data or report content included, only the announcement and procedural information for the AGM. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself. The document length is under 5,000 characters and it is clearly a meeting notice rather than the report itself or voting results.
2025-03-30 Chinese
迈威生物2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm Ernst & Young Hua Ming for the year 2024. It discusses the auditor's background, the appointment process, the audit procedures performed, and the company's assessment of the auditor's performance. It does not contain actual financial statements or detailed financial results but rather an assessment of the auditor's work and independence. The document length is short (1523 characters), and it is a standalone report about audit performance, not the audit report itself or the annual report. Therefore, it fits best under the category of Audit Report / Information (AR).
2025-03-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.